EUVIMEDEUVIMED entdecken
Crossref

A 90‐day toxicity study of tripeptide, arginine‐alanine‐lysine

Maureen Dunn iD, Róbert Glávits, Timothy S Murbach iD, Vickie Modica iD, John R Endres, Gábor Hirka, Ilona Pasics Szakonyiné

Journal of Applied Toxicology · 2023

DOI: 10.1002/jat.4468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Toxicology, 2023. Verfasst von Maureen Dunn und 6 weiteren Autor:innen. Beteiligte Einrichtung: AIBMR Life Sciences, Inc., 1425 Broadway, Suite 458, Seattle, Washington, 98122, USA. Hauptthemen laut MEDLINE: Lysine, Alanine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a growing global interest in using peptides in the health industry for pharmaceuticals, cosmetics, and natural food products. Peptides contain two or more linked amino acids, whereas more than 50 amino acids are classified as polypeptides. Although there is a growing level of interest in the use of peptides in the health and wellness industry, there is a lack of literature pertaining to a specific tripeptide derived from arginine, alanine, and lysine (RAK) that is of interest for human dietary use. Therefore, a 90‐day repeated‐dose toxicity study was performed in rats to evaluate the subchronic oral toxicity of RAK. Eighty Han:WIST rats were administered RAK by gavage at doses of 0, 250, 500, or 1000 mg/kg bw/day. There were no mortalities or other treatment related effects, and no target organs were identified. A no‐observed‐adverse‐effect‐level (NOAEL) of 1000 mg/kg bw/day, the highest dose tested, was determined. This study will contribute to the body of research in regard to the safety of the use of RAK.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LysineAlanineHumansRatsAnimalsArginineNo-Observed-Adverse-Effect LevelAdministration, OralToxicity Tests, Subchronic

Stichwörter der Autor:innen

NOAELRAKalanineargininelysinepeptidesafetytoxicitytripeptide

Substanzen

LysineAlanineArginine

Autor:innen und Institutionen

  • AIBMR Life Sciences, Inc., 1425 Broadway, Suite 458, Seattle, Washington, 98122, USA.
  • Toxi-Coop Zrt., Berlini utca 47-49, H-1045, Budapest, Hungary.

ORCID-Profile: Maureen Dunn, Timothy S Murbach, Vickie Modica

Zitieren

APA

Dunn, M., Glávits, R., Murbach, T. S., Modica, V., Endres, J. R., Hirka, G., & Pasics Szakonyiné, I. (2023). A 90‐day toxicity study of tripeptide, arginine‐alanine‐lysine. Journal of Applied Toxicology. https://doi.org/10.1002/jat.4468

Vancouver

Dunn M, Glávits R, Murbach TS, Modica V, Endres JR, Hirka G, et al. A 90‐day toxicity study of tripeptide, arginine‐alanine‐lysine. Journal of Applied Toxicology. 2023. doi:10.1002/jat.4468

BibTeX
@article{Dunn2023,
  author = {Dunn, Maureen and Glávits, Róbert and Murbach, Timothy S and Modica, Vickie and Endres, John R and Hirka, Gábor and Pasics Szakonyiné, Ilona},
  title = {A 90‐day toxicity study of tripeptide, arginine‐alanine‐lysine},
  journal = {Journal of Applied Toxicology},
  year = {2023},
  doi = {10.1002/jat.4468}
}
Kostenlos starten →